SandeepNayakMD

Postdoctoral Fellow

Dr. Nayak is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1029 East Baltimore Street
Baltimore, MD 21202
Phone+1 410-675-7500

Fax+1 410-367-2352

Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use Start of enrollment: 2023 Dec 01
Withdrawn
Phase 2
Roles: Contact
Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder Start of enrollment: 2024 Feb 08
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder Start of enrollment: 2027 Apr 01
Suspended
Phase 2
Roles: Contact, Principal Investigator
A Study of Psilocybin for PTSD Start of enrollment: 2024 Jun 07
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

PubMed

Practical considerations in the establishment of psychedelic research programs.
Brian S Barnett, M Frances Vest, Marcus S Delatte, Franklin King Iv, Erin E Mauney
Psychopharmacology. 2024-12-04
3 citations
Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis.
Jared T Hinkle, Marianna Graziosi, Sandeep M Nayak, David B Yaden
JAMA Psychiatry. 2024-12-01
Psychedelic risks and benefits: A cross-sectional survey study.
Sean P Goldy, Benjamin A Du, Julia S Rohde, Sandeep M Nayak, Justin C Strickland
Journal of Psychopharmacology. 2024-11-29

Psilocybin and Mental HealthFebruary 13th, 2023
Could 'Magic Mushrooms' Treat Severe Depression? A Major Study Aims to Find OutNovember 2nd, 2022
New Johns Hopkins Study Explores Relationship Between Psychedelics and ConsciousnessMarch 31st, 2022
Join now to see all